Synthorx, spun out of Scripps Research Institute, is targeting $100m in a proposed offering half a year after it raised $63m in a series C round backed by Osage University Partners.

Synthorx, a US-based immuno-oncology drug spinout of Scripps Research Institute, has filed for a $100m initial public offering on the Nasdaq Global Market. Founded in 2014, Synthorx is developing therapeutics, dubbed synthorins, aimed at cancer and autoimmune disorders. Synthorins are proteins that incorporate amino acids encoded by additional DNA base pairs. The approach is based…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.